S1 |
Transfusion support in hematopoietic stem cell transplantationTransfusion support in hematopoietic stem cell transplantation
Dong Wook Jekarl, Jae Kwon Kim, Jay Ho Han, Howon Lee, Jaeeun Yoo, Jihyang Lim, Yonggoo KimDong Wook Jekarl, Jae Kwon Kim, Jay Ho Han, Howon Lee, Jaeeun Yoo, Jihyang Lim, Yonggoo Kim
KMSID: 1516082568 Blood Res. 2023;58(S1):S1-S7. Published online 2023 February 27 DOI: http://dx.doi.org/10.5045/br.2023.2023004 |
|
S8 |
Transfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapyTransfusion thresholds: the need for a patient-centered approach in hematologic disorders that require chronic transfusion therapy
Han Joo Kim, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun KoHan Joo Kim, Sang-Hyun Hwang, Heung-Bum Oh, Dae-Hyun Ko
KMSID: 1516082576 Blood Res. 2023;58(S1):S8-S10. Published online 2023 February 27 DOI: http://dx.doi.org/10.5045/br.2023.2023009 |
|
S11 |
Practical issues in CAR T-cell therapyPractical issues in CAR T-cell therapy
Ja Min ByunJa Min Byun
KMSID: 1516082566 Blood Res. 2023;58(S1):S11-S12. Published online 2023 February 27 DOI: http://dx.doi.org/10.5045/br.2023.2023015 |
|
S13 |
Novel therapeutics for myelofibrosisNovel therapeutics for myelofibrosis
Sung-Eun LeeSung-Eun Lee
KMSID: 1516082569 Blood Res. 2023;58(S1):S13-S19. Published online 2023 March 9 DOI: http://dx.doi.org/10.5045/br.2023.2023012 |
|
S20 |
Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapyManagement of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy
Jae Won YooJae Won Yoo
KMSID: 1516082570 Blood Res. 2023;58(S1):S20-S28. Published online 2023 March 9 DOI: http://dx.doi.org/10.5045/br.2023.2023026 |
|
S29 |
Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinaseAsciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
Eun-Ji ChoiEun-Ji Choi
KMSID: 1516082571 Blood Res. 2023;58(S1):S29-S36. Published online 2023 March 9 DOI: http://dx.doi.org/10.5045/br.2023.2023017 |
|
S37 |
Prognostication in myeloproliferative neoplasms, including mutational abnormalitiesPrognostication in myeloproliferative neoplasms, including mutational abnormalities
Junshik HongJunshik Hong
KMSID: 1516082572 Blood Res. 2023;58(S1):S37-S45. Published online 2023 March 16 DOI: http://dx.doi.org/10.5045/br.2023.2023038 |
|
S46 |
Current status of red blood cell manufacturing in 3D culture and bioreactorsCurrent status of red blood cell manufacturing in 3D culture and bioreactors
Soonho Kweon, Suyeon Kim, Eun Jung BaekSoonho Kweon, Suyeon Kim, Eun Jung Baek
KMSID: 1516082574 Blood Res. 2023;58(S1):S46-S51. Published online 2023 April 7 DOI: http://dx.doi.org/10.5045/br.2023.2023008 |
|
S52 |
T-large granular lymphocytic leukemiaT-large granular lymphocytic leukemia
Sang Hyuk Park, Yoo Jin Lee, Youjin Kim, Hyun-Ki Kim, Ji-Hun Lim, Jae-Cheol JoSang Hyuk Park, Yoo Jin Lee, Youjin Kim, Hyun-Ki Kim, Ji-Hun Lim, Jae-Cheol Jo
KMSID: 1516082573 Blood Res. 2023;58(S1):S52-S57. Published online 2023 April 7 DOI: http://dx.doi.org/10.5045/br.2023.2023037 |
|
S58 |
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemiaTreatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Jae Joon HanJae Joon Han
KMSID: 1516082575 Blood Res. 2023;58(S1):S58-S65. Published online 2023 April 7 DOI: http://dx.doi.org/10.5045/br.2023.2023035 |
|
S66 |
Mycosis fungoides and Sézary syndromeMycosis fungoides and Sézary syndrome
Hyewon LeeHyewon Lee
KMSID: 1516082577 Blood Res. 2023;58(S1):S66-S82. Published online 2023 April 30 DOI: http://dx.doi.org/10.5045/br.2023.2023023 |
|
S83 |
Novel therapeutic strategies for essential thrombocythemia/polycythemia veraNovel therapeutic strategies for essential thrombocythemia/polycythemia vera
Seug Yun Yoon, Jong-Ho WonSeug Yun Yoon, Jong-Ho Won
KMSID: 1516082578 Blood Res. 2023;58(S1):S83-S89. Published online 2023 April 30 DOI: http://dx.doi.org/10.5045/br.2023.2023013 |
|
S90 |
Plasmacytoid dendritic cell neoplasmsPlasmacytoid dendritic cell neoplasms
Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, Jae-Cheol JoYoo Jin Lee, Youjin Kim, Sang Hyuk Park, Jae-Cheol Jo
KMSID: 1516082579 Blood Res. 2023;58(S1):S90-S95. Published online 2023 April 30 DOI: http://dx.doi.org/10.5045/br.2023.2023052 |
|
S96 |
Recent advances in diagnosis and therapy in systemic mastocytosisRecent advances in diagnosis and therapy in systemic mastocytosis
Hyun Jung LeeHyun Jung Lee
KMSID: 1516082580 Blood Res. 2023;58(S1):S96-S108. Published online 2023 April 30 DOI: http://dx.doi.org/10.5045/br.2023.2023024 |
|
S109 |
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantationTreatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Jieun UhmJieun Uhm
KMSID: 1516082567 Blood Res. 2023;58(S1):S109-S113. Published online 2023 April 30 DOI: http://dx.doi.org/10.5045/br.2023.2023054 |
|